Chester County News and Community Website
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) announced the publication of a new retrospective study linking the use of its Titan SGSâ„¢ Stapler with significantly reduced rates of post-operative gastroesophageal …
Study Highlights Reduced Post-Operative GERD Rates Tied to Titan SGS Stapler in Sleeve Gastrectomy Read More
WILMINGTON, DE — AstraZeneca has announced positive high-level results from its Phase III POTOMAC trial assessing the efficacy of IMFINZI® (durvalumab) combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance …
AstraZeneca’s IMFINZI® Demonstrates Promising Results in POTOMAC Phase III Trial for High-Risk NMIBC Read More
SAN DIEGO, CA / TOKYO, Japan / MALVERN, PA — Fujirebio Holdings Inc., its subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. have announced the successful completion of a prospective …
Fujirebio and AriBio Achieve Milestone in Biomarker Advancement for Alzheimer’s Disease Read More WILMINGTON, DE — Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when followed by paclitaxel, trastuzumab, and pertuzumab (THP), significantly improved pathologic complete response (pCR) …
ENHERTU Shows Promise in Early-Stage HER2-Positive Breast Cancer Read More
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of its Phase 3 MAESTRO-NAFLD-1 trial, showcasing the potential of Rezdiffra for treating patients …
Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH Cirrhosis Read More
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, imdusiran and AB-101, at the European Association for the Study of the …
Arbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025 Read More WILMINGTON, DE — AstraZeneca has announced positive high-level results from its Phase III KALOS and LOGOS trials, showing significant promise for its fixed-dose triple-combination therapy, BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or …
AstraZeneca Reports Promising Phase III Trial Results for BREZTRI AEROSPHERE Read More
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) presented preclinical and translational data on its clinical asset, CT-95, at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The …
Context Therapeutics Showcases Promising CT-95 Data at AACR Annual Meeting Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has received FDA approval to move forward with its Virtue Trial, a pivotal clinical study designed to evaluate its next-generation …
Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is set to showcase critical new findings on resmetirom, its liver-targeted thyroid hormone receptor (THR)-β agonist, at the European Association for the …
Madrigal Pharmaceuticals to Present Breakthrough Resmetirom Data at EASL Congress 2025 Read More